Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus DENTIPATCH.
Head-to-head clinical analysis: BUPIVACAINE LIPOSOME versus DENTIPATCH.
BUPIVACAINE LIPOSOME vs DENTIPATCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine liposome is a long-acting local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx through voltage-gated sodium channels in neuronal cell membranes. The liposomal formulation provides sustained release of bupivacaine, prolonging analgesic effect.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Local infiltration: up to 266 mg (20 mL of 1.3% or 10 mL of 2.66%) single dose; interscalene brachial plexus block: up to 133 mg (10 mL of 1.3%) single dose; sciatic nerve block in the popliteal fossa: up to 133 mg (10 mL of 1.3%) single dose; adductor canal block: up to 133 mg (10 mL of 1.3%) single dose; max dose 266 mg per procedure.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
None Documented
None Documented
Terminal elimination half-life is approximately 12-24 hours (mean 18 hours) due to prolonged release from liposomal depot; significantly longer than conventional bupivacaine (2-4 hours), reflecting slow absorption rate-limited elimination.
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Primarily hepatic metabolism to 3-hydroxybupivacaine and desbutylbupivacaine; renal excretion of metabolites accounts for ~95% of elimination, with <5% unchanged drug excreted in urine; biliary/fecal excretion minimal (<5%).
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Category C
Category C
Local Anesthetic
Local Anesthetic